1
|
Yin S, Zhang B, Lin J, Liu Y, Su Z, Bi J. Development of purification process for dual-function recombinant human heavy-chain ferritin by the investigation of genetic modification impact on conformation. Eng Life Sci 2021; 21:630-642. [PMID: 34690634 PMCID: PMC8518560 DOI: 10.1002/elsc.202000105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 05/08/2021] [Accepted: 05/21/2021] [Indexed: 12/02/2022] Open
Abstract
Ferritin is a promising drug delivery platform and has been functionalized through genetic modifications. This work has designed and expressed a dual-functional engineered human heavy-chain ferritin (HFn) with the inserted functional peptide PAS and RGDK to extend half-life and improve tumor targeted drug delivery. A facile and cost-effective two-step purification pathway for recombinant HFn was developed. The genetic modification was found to affect HFn conformation, and therefore varied the purification performance. Heat-acid precipitation followed by butyl fast flow hydrophobic interaction chromatography (HIC) has been developed to purify HFn and modified HFns. Nucleic acid removal reached above 99.8% for HFn and modified HFns. However, HFn purity reached above 95% and recovery yield (overall) above 90%, compared with modified HFns purity above 82% and recovery yield (overall) above 58%. It is interesting to find that the inserted functional peptides significantly changed the molecule conformation, where a putative turnover of the E-helix with the inserted functional peptides formed a "flop" conformation, in contrast with the "flip" conformation of HFn. It could be the cause of fragile stability of modified HFns, and therefore less tolerant to heat and acid condition, observed by the lower recovery yield in heat-acid precipitation.
Collapse
Affiliation(s)
- Shuang Yin
- School of Chemical Engineering & Advanced MaterialsFaculty of Engineering, Computer and Mathematical SciencesUniversity of AdelaideAdelaideAustralia
| | - Bingyang Zhang
- School of Chemical Engineering & Advanced MaterialsFaculty of Engineering, Computer and Mathematical SciencesUniversity of AdelaideAdelaideAustralia
| | - Jianying Lin
- College of Biomedical EngineeringTaiyuan University of TechnologyTaiyuanP. R. China
| | - Yongdong Liu
- State Key Laboratory of Biochemistry EngineeringInstitute of Process EngineeringChinese Academy of SciencesBeijingP. R. China
| | - Zhiguo Su
- State Key Laboratory of Biochemistry EngineeringInstitute of Process EngineeringChinese Academy of SciencesBeijingP. R. China
| | - Jingxiu Bi
- School of Chemical Engineering & Advanced MaterialsFaculty of Engineering, Computer and Mathematical SciencesUniversity of AdelaideAdelaideAustralia
| |
Collapse
|
2
|
Thakare V, Schmidt T, Rupprechter O, Leibold J, Stemmer S, Mischo A, Bhattacharjee D, Prazeller P. Can Cross-Linked Siliconized PFS Come to the Rescue of the Biologics Drug Product? J Pharm Sci 2020; 109:3340-3351. [PMID: 32871152 DOI: 10.1016/j.xphs.2020.08.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 08/19/2020] [Accepted: 08/24/2020] [Indexed: 10/23/2022]
Abstract
Silicone can present a challenge during the development of a biologics drug product particularly in pre-filled syringe (PFS). Due to silicone related challenges, substantial changes in components and manufacturing of the PFS are being sought. Cross-linking of the silicone being one of them, can help reduce mobilization of the silicone into drug product whilst retaining its functionality of lubrication during injection. In this work, we systematically compare the stability of a fusion protein and monoclonal antibody formulation in conventionally siliconized and cross-linked siliconized PFS available from commercial manufacturers. The two types of syringes did not influence the aggregation profile of proteins as determined by HP-SEC. Compared to conventionally siliconized PFS, a cross-linked siliconized PFS can have a favorable or indifferent impact (depending on vendor) on the sub-visible particles profile as assessed by light obscuration and microflow imaging. The different PFS after 24 months of long-term storage showed comparable functionality attributes like break-loose/gliding force and silicone oil distribution. Cross-linked siliconized PFS can offer an incremental advantage over conventionally siliconized PFS for the moderately concentrated protein solutions, however the differences in the quality of these PFS amongst manufacturers is an important aspect that needs to be considered as shown in this study.
Collapse
Affiliation(s)
- Vivek Thakare
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria.
| | - Thomas Schmidt
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - Olga Rupprechter
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - Julia Leibold
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - Susanne Stemmer
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - André Mischo
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - Debarati Bhattacharjee
- Novartis, Biopharmaceutical Product & Process Development, Global Drug Development, Schaftenau, Austria
| | - Peter Prazeller
- Novartis, Device Development & Commercialization, Schaftenau, Austria
| |
Collapse
|
3
|
Kulakova A, Indrakumar S, Sønderby Tuelung P, Mahapatra S, Streicher WW, Peters GHJ, Harris P. Albumin-neprilysin fusion protein: understanding stability using small angle X-ray scattering and molecular dynamic simulations. Sci Rep 2020; 10:10089. [PMID: 32572086 PMCID: PMC7308280 DOI: 10.1038/s41598-020-67002-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 05/27/2020] [Indexed: 12/16/2022] Open
Abstract
Fusion technology is widely used in protein-drug development to increase activity, stability, and bioavailability of protein therapeutics. Fusion proteins, like any other type of biopharmaceuticals, need to remain stable during production and storage. Due to the high complexity and additional intramolecular interactions, it is not possible to predict the behavior of fusion proteins based on the behavior the individual proteins. Therefore, understanding the stability of fusion proteins on the molecular level is crucial for the development of biopharmaceuticals. The current study on the albumin-neprilysin (HSA-NEP) fusion protein uses a combination of thermal and chemical unfolding with small angle X-ray scattering and molecular dynamics simulations to show a correlation between decreasing stability and increasing repulsive interactions, which is unusual for most biopharmaceuticals. It is also seen that HSA-NEP is not fully flexible: it is present in both compact and extended conformations. Additionally, the volume fraction of each conformation changes with pH. Finally, the presence of NaCl and arginine increases stability at pH 6.5, but decreases stability at pH 5.0.
Collapse
Affiliation(s)
- Alina Kulakova
- Department of Chemistry, Technical University of Denmark, Kemitorvet building 207, Kgs. Lyngby, 2800, Denmark
| | - Sowmya Indrakumar
- Department of Chemistry, Technical University of Denmark, Kemitorvet building 207, Kgs. Lyngby, 2800, Denmark
| | - Pernille Sønderby Tuelung
- Department of Chemistry, Technical University of Denmark, Kemitorvet building 207, Kgs. Lyngby, 2800, Denmark
| | | | | | - Günther H J Peters
- Department of Chemistry, Technical University of Denmark, Kemitorvet building 207, Kgs. Lyngby, 2800, Denmark
| | - Pernille Harris
- Department of Chemistry, Technical University of Denmark, Kemitorvet building 207, Kgs. Lyngby, 2800, Denmark.
| |
Collapse
|
4
|
Cho J, Park J, Kim S, Kim JC, Tae G, Jin MS, Kwon I. Intramolecular distance in the conjugate of urate oxidase and fatty acid governs FcRn binding and serum half-life in vivo. J Control Release 2020; 321:49-58. [DOI: 10.1016/j.jconrel.2020.01.034] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Accepted: 01/18/2020] [Indexed: 12/17/2022]
|
5
|
Sharma A, Chaudhuri TK. Physicochemical characterization of E. coli -derived human serum albumin and its comparison with the human plasma counterpart reveals it as a promising biosimilar. J Biotechnol 2018. [DOI: 10.1016/j.jbiotec.2018.03.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
6
|
Herrington-Symes A, Choi JW, Brocchini S. Interferon dimers: IFN-PEG-IFN. J Drug Target 2017; 25:881-890. [PMID: 28817988 DOI: 10.1080/1061186x.2017.1363214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Increasingly complex proteins can be made by a recombinant chemical approach where proteins that can be made easily can be combined by site-specific chemical conjugation to form multifunctional or more active protein therapeutics. Protein dimers may display increased avidity for cell surface receptors. The increased size of protein dimers may also increase circulation times. Cytokines bind to cell surface receptors that dimerise, so much of the solvent accessible surface of a cytokine is involved in binding to its target. Interferon (IFN) homo-dimers (IFN-PEG-IFN) were prepared by two methods: site-specific bis-alkylation conjugation of PEG to the two thiols of a native disulphide or to two imidazoles on a histidine tag of two His8-tagged IFN (His8IFN). Several control conjugates were also prepared to assess the relative activity of these IFN homo-dimers. The His8IFN-PEG20-His8IFN obtained by histidine-specific conjugation displayed marginally greater in vitro antiviral activity compared to the IFN-PEG20-IFN homo-dimer obtained by disulphide re-bridging conjugation. This result is consistent with previous observations in which enhanced retention of activity was made possible by conjugation to an N-terminal His-tag on the IFN. Comparison of the antiviral and antiproliferative activities of the two IFN homo-dimers prepared by disulphide re-bridging conjugation indicated that IFN-PEG10-IFN was more biologically active than IFN-PEG20-IFN. This result suggests that the size of PEG may influence the antiviral activity of IFN-PEG-IFN homo-dimers.
Collapse
Affiliation(s)
| | - Ji-Won Choi
- a Abzena , Babraham Research Campus , Babraham, Cambridge , UK
| | | |
Collapse
|
7
|
Yang B, Lim SI, Kim JC, Tae G, Kwon I. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo. Biomacromolecules 2016; 17:1811-7. [PMID: 27050863 DOI: 10.1021/acs.biomac.6b00238] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Polyethylene glycol (PEG) has been widely used as a serum half-life extender of therapeutic proteins. However, due to immune responses and low degradability of PEG, developing serum half-life extender alternatives to PEG is required. Human serum albumin (HSA) has several beneficial features as a serum half-life extender, including a very long serum half-life, good degradability, and low immune responses. In order to further evaluate the efficacy of HSA, we compared the extent of serum half-life extension of a target protein, superfolder green fluorescent protein (sfGFP), upon HSA conjugation with PEG conjugation side-by-side. Combination of site-specific incorporation of p-azido-l-phenylalanine into sfGFP and copper-free click chemistry achieved the site-specific conjugation of a single HSA, 20 kDa PEG, or 30 kDa PEG to sfGFP. These sfGFP conjugates exhibited the fluorescence comparable to or even greater than that of wild-type sfGFP (sfGFP-WT). In mice, HSA-conjugation to sfGFP extended the serum half-life 9.0 times compared to that of unmodified sfGFP, which is comparable to those of PEG-conjugated sfGFPs (7.3 times for 20 kDa PEG and 9.5 times for 30 kDa PEG). These results clearly demonstrated that HSA was as effective as PEG in extending the serum half-life of a target protein. Therefore, with the additional favorable features, HSA is a good serum half-life extender of a (therapeutic) protein as an alternative to PEG.
Collapse
Affiliation(s)
- Byungseop Yang
- School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST) , Gwangju 61005, Republic of Korea
| | - Sung In Lim
- Department of Chemical Engineering, University of Virginia , Charlottesville, Virginia 22904, United States
| | - Jong Chul Kim
- School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST) , Gwangju 61005, Republic of Korea
| | - Giyoong Tae
- School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST) , Gwangju 61005, Republic of Korea
| | - Inchan Kwon
- School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST) , Gwangju 61005, Republic of Korea.,Department of Chemical Engineering, University of Virginia , Charlottesville, Virginia 22904, United States
| |
Collapse
|
8
|
Abstract
The Fc-fusion mimetic RpR 2̲ was prepared by disulfide bridging conjugation using PEG in the place of the Fc.
Collapse
Affiliation(s)
- H. Khalili
- UCL School of Pharmacy
- University College London
- London WC1N 1AX
- UK
- NIHR Biomedical Research Centre
| | - P. T. Khaw
- NIHR Biomedical Research Centre
- Moorfields Eye Hospital and UCL Institute of Ophthalmology
- London
- UK
| | - S. Brocchini
- UCL School of Pharmacy
- University College London
- London WC1N 1AX
- UK
- NIHR Biomedical Research Centre
| |
Collapse
|
9
|
Lim SI, Hahn YS, Kwon I. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. J Control Release 2015; 207:93-100. [PMID: 25862515 PMCID: PMC4430413 DOI: 10.1016/j.jconrel.2015.04.004] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Revised: 02/03/2015] [Accepted: 04/05/2015] [Indexed: 11/21/2022]
Abstract
Albumin fusion/conjugation (albumination) has been an effective method to prolong in vivo half-life of therapeutic proteins. However, its broader application to proteins with complex folding pathway or multi-subunit is restricted by incorrect folding, poor expression, heterogeneity, and loss of native activity of the proteins linked to albumin. We hypothesized that the site-specific conjugation of albumin to a permissive site of a target protein will expand the utilities of albumin as a therapeutic activity extender to proteins with a complex structure. We show here the genetic incorporation of a non-natural amino acid (NNAA) followed by chemoselective albumin conjugation to prolong therapeutic activity in vivo. Urate oxidase (Uox), a therapeutic enzyme for treatment of hyperuricemia, is a homotetramer with multiple surface lysines, limiting conventional approaches for albumination. Incorporation of p-azido-l-phenylalanine into two predetermined positions of Uox allowed site-specific linkage of dibenzocyclooctyne-derivatized human serum albumin (HSA) through strain-promoted azide-alkyne cycloaddition (SPAAC). The bio-orthogonality of SPAAC resulted in the production of a chemically well-defined conjugate, Uox-HSA, with a retained enzymatic activity. Uox-HSA had a half-life of 8.8 h in mice, while wild-type Uox had a half-life of 1.3 h. The AUC increased 5.5-fold (1657 vs. 303 mU/mL x h). These results clearly demonstrated that site-specific albumination led to the prolonged enzymatic activity of Uox in vivo. Site-specific albumination enabled by NNAA incorporation and orthogonal chemistry demonstrates its promise for the development of long-acting protein therapeutics with high potency and safety.
Collapse
Affiliation(s)
- Sung In Lim
- Department of Chemical Engineering, University of Virginia, VA 22904, United States
| | - Young S Hahn
- Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, VA 22908, United States
| | - Inchan Kwon
- Department of Chemical Engineering, University of Virginia, VA 22904, United States; School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea.
| |
Collapse
|
10
|
Abstract
It is well recognized that protein product development is far more challenging than that for small-molecule drugs. The major challenges include inherent sensitivity to different types of stresses during the drug product manufacturing process, high rate of physical and chemical degradation during long-term storage, and enhanced aggregation and/or viscosity at high protein concentrations. In the past decade, many novel formulation concepts and technologies have been or are being developed to address these product development challenges for proteins. These concepts and technologies include use of uncommon/combination of formulation stabilizers, conjugation or fusion with potential stabilizers, site-specific mutagenesis, and preparation of nontraditional types of dosage forms-semiaqueous solutions, nonfreeze-dried solid formulations, suspensions, and other emerging concepts. No one technology appears to be mature, ideal, and/or adequate to address all the challenges. These gaps will likely remain in the foreseeable future and need significant efforts for ultimate resolution.
Collapse
Affiliation(s)
- Wei Wang
- BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO, 63017.,Wang Biologics, LLC, 907 Wellesley Place, Chesterfield, Missouri, 63017
| |
Collapse
|
11
|
|
12
|
Mehta SB, Bee JS, Randolph TW, Carpenter JF. Partial unfolding of a monoclonal antibody: role of a single domain in driving protein aggregation. Biochemistry 2014; 53:3367-77. [PMID: 24804773 DOI: 10.1021/bi5002163] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We have examined the effect of incubating a monoclonal antibody (mAb) in low (0-2.0 M) concentrations of guanidine hydrochloride (GdnHCl) on the protein's conformation and aggregation during isothermal incubation. In GdnHCl solutions at concentrations from 1.2 to 1.6 M, the mAb was partially unfolded. As demonstrated by fluorescence and circular dichroism spectroscopy, the partially unfolded state of the antibody had perturbed tertiary structure but retained native secondary structure. Furthermore, partial unfolding of the antibody was documented by analytical ultracentrifugation, dynamic light scattering, and limited proteolysis. Subsequent aggregation of the antibody was characterized using size-exclusion chromatography, analytical ultracentrifugation, and dynamic light scattering. Over the entire concentration range (0-2.0 M) of GdnHCl, protein-protein interactions were attractive, as quantified by negative osmotic second virial coefficients measured with static light scattering. However, during isothermal incubation at 37 °C, the aggregation of the antibody was detected only in solutions that induced partial unfolding. Differential scanning calorimetry studies showed that the antibody's CH2 domains were unfolded in antibody molecules that had been incubated in 1.2 M and higher concentrations of GdnHCl. These results suggest that unfolding of the CH2 domains leads to aggregation.
Collapse
Affiliation(s)
- Shyam B Mehta
- Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States
| | | | | | | |
Collapse
|
13
|
Faroongsarng D, Kongprasertkit J. The role of caprylate ligand ion on the stabilization of human serum albumin. AAPS PharmSciTech 2014; 15:465-71. [PMID: 24470225 DOI: 10.1208/s12249-014-0076-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Accepted: 12/23/2013] [Indexed: 12/12/2022] Open
Abstract
Sodium caprylate was added to a pharmaceutical-grade human serum albumin (HSA) to stabilize the product. In this study we have aimed to establish how caprylate ligand protects HSA from thermal degradation. The fatty acid stabilizer was first removed from commercial HSA by charcoal treatment. Cleaned HSA was made to 10% w/v in pH 7.4 buffered solutions and doped with sodium caprylate in serial concentrations up to 0.16 mmol/g-protein. These solutions as well as a commercial HSA, human serum, and enriched-albumin fraction were subjected to differential scanning calorimetry (DSC) within the temperature range of 37-90°C at a 5.0°C/min scanning rate. The globular size of the cleaned HSA solutions was measured by dynamic light scattering. The denaturing temperatures for albumin with sodium caprylate and a commercial one were significantly higher than for albumin only. It was found that the protein globules of cleaned HSA were not as stable as that of the native one due to aggregation, and the caprylate ion may reduce the aggregation by enlarging the globules' electrical double layer. A rational approximation of the Lumry-Eyring protein denaturation model was used to treat DSC denaturing endotherms. The system turned from irreversible dominant Scheme: N (k3K)→ P to reversible dominant Scheme:N (k1)→ P with the increase in caprylate concentration from null to ~0.08 mmol/g-protein. It was postulated that the caprylate ligand may decrease the rate of reversible unfolding as it binds to the IIIA domain which is prone to reversible unfolding/refolding and causes further difficulty for irreversible denaturation which, in turn, HSA can be stabilized.
Collapse
|
14
|
Khalili H, Godwin A, Choi JW, Lever R, Khaw PT, Brocchini S. Fab-PEG-Fab as a Potential Antibody Mimetic. Bioconjug Chem 2013; 24:1870-82. [DOI: 10.1021/bc400246z] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Hanieh Khalili
- UCL
School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
- NIHR
Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, EC1 V 9EL, United Kingdom
| | - Antony Godwin
- PolyTherics
Ltd, The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, United Kingdom
| | - Ji-won Choi
- PolyTherics
Ltd, The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, United Kingdom
| | - Rebecca Lever
- UCL
School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Peng T. Khaw
- NIHR
Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, EC1 V 9EL, United Kingdom
| | - Steve Brocchini
- UCL
School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
- NIHR
Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, EC1 V 9EL, United Kingdom
| |
Collapse
|
15
|
Hamborg M, Kramer R, Schanté CE, Agger EM, Christensen D, Jorgensen L, Foged C, Middaugh CR. The physical stability of the recombinant tuberculosis fusion antigens h1 and h56. J Pharm Sci 2013; 102:3567-78. [PMID: 23873630 DOI: 10.1002/jps.23669] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 06/03/2013] [Accepted: 06/24/2013] [Indexed: 01/13/2023]
Abstract
The recombinant fusion proteins hybrid 1 [H1 (Ag85B-ESAT-6)] and hybrid 56 [H56 (Ag85B-ESAT-6-Rv2660c)] derived from Mycobacterium tuberculosis are promising antigens for subunit vaccines against tuberculosis. Both antigens are early batches of antigens to be enrolled in human clinical trials and it is therefore important to characterize their conformational stability in solution as well as upon interaction with adjuvants. In this study, the physical stability of the two antigens was characterized using a number of biophysical techniques. Dynamic light scattering and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses demonstrated that both antigens exist as a distribution of multimeric states under nonstressed conditions. Their conformational stability was monitored as a function of pH and temperature and visualized in three-index empirical phase diagrams. Both antigens showed a gradual loss of secondary as well as tertiary structure as a function of temperature, with no cooperative transitions observed. Preformulation studies with the Th1-inducing cationic adjuvant CAF01 showed that the antigens were almost completely surface adsorbed. Upon adsorption, the liposome size increased; however, the physical stabilities of the bound and the unbound antigens were comparable. This study provides important information about the biophysical properties of H1 and H56 and highlights the analytical challenges of characterizing complex vaccine formulations.
Collapse
Affiliation(s)
- Mette Hamborg
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen Ø, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta Gen Subj 2013; 1830:5526-34. [PMID: 23639804 DOI: 10.1016/j.bbagen.2013.04.023] [Citation(s) in RCA: 331] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 04/16/2013] [Accepted: 04/17/2013] [Indexed: 01/10/2023]
Abstract
BACKGROUND Albumin is the most abundant plasma protein, is highly soluble, very stable and has an extraordinarily long circulatory half-life as a direct result of its size and interaction with the FcRn mediated recycling pathway. In contrast, many therapeutic molecules are smaller than the renal filtration threshold and are rapidly lost from the circulation thereby limiting their therapeutic potential. Albumin can be used in a variety of ways to increase the circulatory half-life of such molecules. SCOPE OF REVIEW This article will review the mechanisms which underpin albumin's extraordinarily long circulatory half-life and how the understanding of these processes are currently being employed to extend the circulatory half-life of drugs which can be engineered to bind to albumin, or are conjugated to, or genetically fused to, albumin. MAJOR CONCLUSIONS The recent and growing understanding of the pivotal role of FcRn in maintaining the extended circulatory half-life of albumin will necessitate a greater and more thorough investigation of suitable pre-clinical model systems for assessing the pharmacokinetic profiles of drugs associated, conjugated or fused to albumin. GENERAL SIGNIFICANCE Association, conjugation or fusion of therapeutic drugs to albumin is a well-accepted and established half-life extension technology. The manipulation of the albumin-FcRn interaction will facilitate the modulation of the circulatory half-life of albumin-enabled drugs, leading to superior pharmacokinetics tailored to the disease state and increased patient compliance. This article is part of a Special Issue entitled Serum Albumin.
Collapse
|
17
|
Brunsteiner M, Flock M, Nidetzky B. Structure based descriptors for the estimation of colloidal interactions and protein aggregation propensities. PLoS One 2013; 8:e59797. [PMID: 23565169 PMCID: PMC3614552 DOI: 10.1371/journal.pone.0059797] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Accepted: 02/19/2013] [Indexed: 11/19/2022] Open
Abstract
The control of protein aggregation is an important requirement in the development of bio-pharmaceutical formulations. Here a simple protein model is proposed that was used in molecular dynamics simulations to obtain a quantitative assessment of the relative contributions of proteins' net-charges, dipole-moments, and the size of hydrophobic or charged surface patches to their colloidal interactions. The results demonstrate that the strength of these interactions correlate with net-charge and dipole moment. Variation of both these descriptors within ranges typical for globular proteins have a comparable effect. By comparison no clear trends can be observed upon varying the size of hydrophobic or charged patches while keeping the other parameters constant. The results are discussed in the context of experimental literature data on protein aggregation. They provide a clear guide line for the development of improved algorithms for the prediction of aggregation propensities.
Collapse
Affiliation(s)
- Michael Brunsteiner
- Research Center Pharmaceutical Engineering, Graz, Austria
- Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, Graz, Austria
| | - Michaela Flock
- Institute of Inorganic Chemistry, Graz University of Technology, Graz, Austria
| | - Bernd Nidetzky
- Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, Graz, Austria
| |
Collapse
|
18
|
Cordes AA, Carpenter JF, Randolph TW. Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate. J Pharm Sci 2012; 101:2009-16. [PMID: 22422106 DOI: 10.1002/jps.23118] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2011] [Revised: 02/05/2012] [Accepted: 02/14/2012] [Indexed: 02/03/2023]
Abstract
Therapeutic proteins must be generally formulated to reduce unwanted aggregation. Fusion proteins, which comprise domains assembled from separate proteins, may require unique formulation strategies in order to maximize their stability. A fusion protein of human serum albumin (HSA) and human granulocyte colony stimulating factor (GCSF; HSA-GCSF) was used as a model to test the hypothesis that formulations that increase the thermodynamic conformational stability of the least stable domain of a fusion protein will stabilize the entire fusion protein against aggregation. Conformational stability of HSA-GCSF was modulated by addition of octanoic acid, which was previously shown to increase the conformational stability of HSA, the least stable domain. Contrary to our hypothesis, increased conformational stability of the HSA domain did not result in increased resistance to aggregation of HSA-GCSF. These results for HSA-GCSF were also compared with similar studies conducted previously on a therapeutic protein formed by the fusion of HSA and human growth hormone (hGH; HSA-hGH).
Collapse
Affiliation(s)
- Amanda A Cordes
- Department of Chemical and Biological Engineering, Center for Pharmaceutical Biotechnology, University of Colorado, Boulder, Colorado 80309, USA
| | | | | |
Collapse
|